

FOR YOUR PATIENTS WITH HR+, HER2-, NODE-POSITIVE, EARLY-STAGE, INVASIVE BREAST CANCER

It's never been as clear™

**N1**  
RxPONDER  
initial practice-changing results<sup>1,2</sup>

To identify node-positive (N1) patients who can be spared chemotherapy

- ✓ **RxPONDER results add to findings of SWOG-8814**, the study that established the **Oncotype DX® test as predictive of chemotherapy benefit in N1 post-menopausal patients<sup>a,1,3</sup>**
- ✓ **The majority of N1 post-menopausal patients can now be spared chemotherapy** based on Recurrence Score® results 0-25, regardless of clinical pathological parameters<sup>1</sup>
- ✓ **N1 pre-menopausal** patients with Recurrence Score® results 0-25, derived a **2.9% benefit from chemotherapy** based on distant recurrence at 5 years<sup>1</sup>

N1 RxPONDER and SWOG-8814

The Oncotype DX Breast Recurrence Score® test guides treatment decisions with precision for N1 post-menopausal patients<sup>1,3</sup>

	Recurrence Score® result 0-25	RS® result 26-100	
<b>Post-menopausal<sup>1,2</sup></b>	No chemotherapy benefit	Substantial CT benefit	5-year outcomes
<b>Pre-menopausal<sup>1</sup></b> 33% of patients in RxPONDER	2.9% chemotherapy benefit	Substantial CT benefit <sup>a</sup>	5-year outcomes

Chemotherapy benefit expressed in percentage points based on probability of distant recurrence with/without chemotherapy at 5 years  
No chemotherapy benefit is considered for an absolute benefit <1%.

<sup>a</sup> The benefit of chemotherapy in pre-menopausal N1 patients with Recurrence Score® results 26-100 has not been assessed in a randomised study. The benefit derived from chemotherapy was significant for Recurrence Score® results 0-13 and 14-25 in the RxPONDER study, and it is thus inferred to be substantial for patients with Recurrence Score® results 26-100.

HR+=hormone receptor positive; HER2-=human epidermal growth factor receptor 2 negative; N1=1-3 positive nodes; RxPONDER=a clinical trial Rx for PPositive NoDe, Endocrine Responsive breast cancer; CT=chemotherapy

**References:** **1.** Kalinsky et al. SABCs 2020. GS3-00. **2.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed 10 May, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. **3.** Albain et al. *Lancet Oncol.* 2010.

Sole Distributor



Jacobson Medical (Hong Kong) Ltd  
Tel: (852) 2596 1832 Fax: (852) 2790 9300  
Email: sales@jacobsonmedical.com.hk

Oncotype DX Breast Recurrence Score, Oncotype DX, Recurrence Score, RS and It's never been as clear are trademarks or registered trademarks of Genomic Health, Inc. Used under licence. © 2021 Genomic Health, Inc. All rights reserved. EXS13254\_0921\_EN\_HK

oncotypeDX®  
Breast Recurrence Score